MOUNTAIN VIEW, Calif.,
Nov. 21, 2013 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today
that the Company will participate in the 25th Annual
Piper Jaffray Healthcare Conference, being held in New York, NY, on December 3 - 4, 2013. Thomas B. King, Alexza
President and CEO, will present at the conference. The
Alexza corporate presentation will be Tuesday, December 3, 2013 at 2:30 p.m. Eastern Time. The presentation
will be webcast live.
To access the presentation via the Web, please go to the Alexza
Investor Relations tab at www.alexza.com or at
http://www.media-server.com/m/p/ojwv3h6t. A replay of the
webcast will be available approximately 24 hours after the
presentation and archived for 30 days.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development
and commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE (Staccato loxapine) is Alexza's first commercial
product, which was approved by the U.S. Food and Drug
Administration in December 2012 and
by the European Commission in February 2013. Teva
Pharmaceuticals USA, Inc. is
Alexza's commercial partner for ADASUVE in the U.S.
Grupo Ferrer Internacional, S.A. is
Alexza's commercial partner for ADASUVE in Europe, Latin
America, Russia and the
Commonwealth of Independent States countries.
For more information about Alexza, the Staccato system
technology or the Company's development programs, please visit
www.alexza.com. For more information about ADASUVE, please
visit www.adasuve.com.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated presentation will contain
forward-looking statements that involve significant risks and
uncertainties. Any statement describing the Company's expectations
or beliefs is a forward-looking statement, as defined in the
Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the
process of developing and commercializing drugs, including the
ability of Alexza and our partners, Teva and Ferrer, to effectively
and profitably commercialize ADASUVE, estimated product revenues
and royalties associated with the sale of ADASUVE, the adequacy of
the Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2012 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.